[go: up one dir, main page]

HK1006810A1 - Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage - Google Patents

Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage

Info

Publication number
HK1006810A1
HK1006810A1 HK98105965A HK98105965A HK1006810A1 HK 1006810 A1 HK1006810 A1 HK 1006810A1 HK 98105965 A HK98105965 A HK 98105965A HK 98105965 A HK98105965 A HK 98105965A HK 1006810 A1 HK1006810 A1 HK 1006810A1
Authority
HK
Hong Kong
Prior art keywords
compositions
neuronal damage
conotoxin peptide
peptide derivatives
treating ischemia
Prior art date
Application number
HK98105965A
Other languages
English (en)
Inventor
George P Miljanich
Roberts S Bitner
Stephen S Bowersox
James A Fox
Karen L Valentino
Donald H Yamashiro
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of HK1006810A1 publication Critical patent/HK1006810A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
HK98105965A 1989-11-22 1998-06-22 Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage HK1006810A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/440,094 US5051403A (en) 1989-11-22 1989-11-22 Method of treating ischemia-related neuronal damage
PCT/US1990/006853 WO1991007980A1 (en) 1989-11-22 1990-11-21 Compositions for treating ischemia-related neuronal damage

Publications (1)

Publication Number Publication Date
HK1006810A1 true HK1006810A1 (en) 1999-03-19

Family

ID=23747411

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98105965A HK1006810A1 (en) 1989-11-22 1998-06-22 Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage

Country Status (12)

Country Link
US (1) US5051403A (ja)
EP (1) EP0593450B1 (ja)
JP (1) JP3809184B2 (ja)
AT (1) ATE140388T1 (ja)
AU (1) AU648052B2 (ja)
CA (1) CA2045473C (ja)
DE (1) DE69027865T2 (ja)
DK (1) DK0593450T3 (ja)
ES (1) ES2091906T3 (ja)
GR (1) GR3021087T3 (ja)
HK (1) HK1006810A1 (ja)
WO (1) WO1991007980A1 (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926713T2 (de) 1988-04-04 1996-11-14 Salk Inst Biotech Ind Calciumkanal-zusammensetzungen und verfahren
US5851824A (en) * 1988-04-04 1998-12-22 Sibia Neurosciences, Inc. Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
CA2151741C (en) * 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
EP0556160A3 (en) * 1992-02-11 1993-10-27 Sandoz Ag Insecticidal toxins from plectreurys tristis
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
PT835126E (pt) * 1995-06-27 2003-07-31 Elan Pharm Inc Composicoes e formulacoes para a producao de analgesia e para a inibicao de patologias dolorosas neuropaticas
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU6415999A (en) * 1998-10-06 2000-04-26 Cognetix, Inc. Kappa-a conopeptides and uses therefor
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
CA2361138A1 (en) 1999-01-22 2000-07-27 University Of Utah Research Foundation Alpha-conotoxin peptides
EP1210100B1 (en) * 1999-08-10 2006-06-14 UAB Research Foundation Method of treating traumatic brain using non-steroidal anti-inflammatory drugs
US6762165B2 (en) 1999-12-30 2004-07-13 University Of Utah Research Foundation O-superfamily conotoxin peptides
EP2386566A3 (en) 2002-12-02 2012-02-15 Xenome Ltd Chi-conotoxin peptides (II)
DK1572725T3 (da) 2002-12-02 2012-06-18 Xenome Ltd Chi-conotoksinpeptider med en N-terminal pyroglutaminsyre
US20090062211A1 (en) * 2003-03-05 2009-03-05 Florida Atlantic University Conopeptides and methods of use
US20060019892A1 (en) * 2003-03-05 2006-01-26 Florida Atlantic University Conopeptides and methods of use
CA2930900C (en) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinations of ziconotide and opioids for reducing pain
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
CN1304422C (zh) * 2005-09-15 2007-03-14 浙江大学 非酰胺化ω－芋螺毒素M ⅦA 及其制备方法和应用
SI1963280T1 (sl) * 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
US8519000B2 (en) 2007-06-15 2013-08-27 Newron Pharmaceuticals S.P.A. Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
WO2011032233A1 (en) 2009-09-21 2011-03-24 The University Of Queensland Novel omega conotoxin peptides
RS55240B1 (sr) 2011-06-27 2017-02-28 Newron Pharm Spa Fluorisani derivati arilalkilaminokarboksamida
US10519324B2 (en) 2015-05-22 2019-12-31 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels

Also Published As

Publication number Publication date
JPH05501715A (ja) 1993-04-02
CA2045473A1 (en) 1991-05-23
DE69027865T2 (de) 1997-01-02
CA2045473C (en) 2002-09-17
WO1991007980A1 (en) 1991-06-13
DE69027865D1 (de) 1996-08-22
ATE140388T1 (de) 1996-08-15
US5051403A (en) 1991-09-24
GR3021087T3 (en) 1996-12-31
JP3809184B2 (ja) 2006-08-16
ES2091906T3 (es) 1996-11-16
AU648052B2 (en) 1994-04-14
DK0593450T3 (da) 1996-11-25
EP0593450B1 (en) 1996-07-17
AU6964091A (en) 1991-06-26
EP0593450A1 (en) 1994-04-27

Similar Documents

Publication Publication Date Title
HK1006810A1 (en) Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage
CS149192A3 (en) Pharmaceutical composition, process of its preparation and method offungal infections treating
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
PL316416A1 (en) Pharmaceutic agent exhibiting immunoregulating and psychotropic properties, therapeutic form thereof and method of treating diseases of immunological and physical background
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
JPS5231839A (en) Drug for cosmetics and permanent wave in combination
SE9603725D0 (sv) New teatment
DE2962580D1 (en) 7-phenyl-quinolizidine derivatives (i), their preparation, pharmaceutical compositions containing them and (i) for use in treating diseases
HUT68007A (en) Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
IE870577L (en) Topical amide preparation
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
EP0456842A4 (en) Medicinal application of m-csf
ZA843489B (en) 4-oxothiazolidin-2-ylidene-acetamide derivatives,processes for their preparation and their use in the combating of diseases of the central nervous system
NZ229928A (en) Substituted cycloalkylthiazole derivatives; preparatory processes and pharmaceutical compositions to treat bronchopulmonary constrictions
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DE3851938D1 (de) Polyaromatische Ester von makroliden Antibiotika und linkosamiden Antibiotika, Verfahren zu ihrer Herstellung und diese enthaltenden pharmazeutischen und kosmetischen Zusammensetzungen.
EP0001051A3 (en) Derivatives of benzenesulfonamide, method for their preparation and their use in treating human hypertension
DK0486586T3 (da) Kynurensyrederivater, fremstilling deraf og farmaceutiske præparater, der indeholder dem
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
EP0478660A4 (en) Pharmaceutical compositions and methods for treating inflammation
HUT62789A (en) Process for producing pharmaceutical composition comprising r(+)-3-amino-1-hydroxypyrroliden-2-one as active ingredient and suitable for treating anxiety
ATA901889A (de) Verfahren zur herstellung von wasserlöslichem primycin und seinen komponenten sowie von diese enthaltenden pharmazeutischen präparaten

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081121